Met Life Investment Management, LLC Keros Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 17,071 shares of KROS stock, worth $966,560. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,071
Previous 17,071 -0.0%
Holding current value
$966,560
Previous $780,000 27.05%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$44.58 - $66.89 $175,110 - $262,743
3,928 Added 29.89%
17,071 $780,000
Q1 2024

May 14, 2024
BUY
$41.26 - $70.48 $542,280 - $926,318
13,143 New
13,143 $870,000
Q3 2023

May 09, 2024
BUY
$31.57 - $43.02 $56,447 - $76,919
1,788 Added 17.71%
11,885 $378,000
Q2 2023

Apr 29, 2024
BUY
$37.26 - $51.01 $442,835 - $606,253
11,885 New
11,885 $477,000
Q2 2023

Aug 10, 2023
BUY
$37.26 - $51.01 $66,620 - $91,205
1,788 Added 17.71%
11,885 $477,000
Q1 2023

May 09, 2024
BUY
$41.44 - $59.32 $418,419 - $598,954
10,097 New
10,097 $431 Million
Q4 2022

May 10, 2024
BUY
$39.45 - $51.77 $64,776 - $85,006
1,642 Added 19.42%
10,097 $484,000
Q4 2022

Mar 22, 2023
BUY
$39.45 - $51.77 $64,776 - $85,006
1,642 Added 19.42%
10,097 $484,000
Q4 2022

Feb 15, 2023
BUY
$39.45 - $51.77 $64,776 - $85,006
1,642 Added 19.42%
10,097 $484,000
Q3 2022

Jun 14, 2023
SELL
$27.8 - $40.12 $45,647 - $65,877
-1,642 Reduced 16.26%
8,455 $318,000
Q2 2022

Jun 20, 2023
SELL
$26.03 - $67.04 $42,741 - $110,079
-1,642 Reduced 16.26%
8,455 $233,000
Q1 2022

May 10, 2024
BUY
$42.12 - $59.36 $356,124 - $501,888
8,455 New
8,455 $459,000
Q1 2022

Jun 20, 2023
SELL
$42.12 - $59.36 $69,161 - $97,469
-1,642 Reduced 16.26%
8,455 $459,000
Q1 2022

Mar 22, 2023
BUY
$42.12 - $59.36 $126,317 - $178,020
2,999 Added 54.97%
8,455 $459,000
Q1 2022

May 12, 2022
BUY
$42.12 - $59.36 $126,317 - $178,020
2,999 Added 54.97%
8,455 $460,000
Q4 2021

Jun 21, 2023
SELL
$36.95 - $62.89 $171,484 - $291,872
-4,641 Reduced 45.96%
5,456 $319,000
Q3 2021

Jun 21, 2023
SELL
$29.27 - $43.71 $135,842 - $202,858
-4,641 Reduced 45.96%
5,456 $215,000
Q2 2021

Jun 21, 2023
SELL
$42.4 - $70.11 $196,778 - $325,380
-4,641 Reduced 45.96%
5,456 $231,000
Q1 2021

May 17, 2024
SELL
$54.0 - $75.28 $415,098 - $578,677
-7,687 Reduced 58.49%
5,456 $335,000
Q1 2021

Jun 26, 2023
SELL
$54.0 - $75.28 $250,614 - $349,374
-4,641 Reduced 45.96%
5,456 $336 Million
Q4 2020

May 24, 2024
BUY
$36.0 - $82.74 $59,256 - $136,190
1,646 Added 43.2%
5,456 $384,000
Q4 2020

Jun 22, 2023
SELL
$36.0 - $82.74 $167,076 - $383,996
-4,641 Reduced 45.96%
5,456 $384,000
Q4 2020

Mar 22, 2023
BUY
$36.0 - $82.74 $59,256 - $136,190
1,646 Added 43.2%
5,456 $384,000
Q4 2020

Feb 16, 2021
BUY
$36.0 - $82.74 $59,256 - $136,190
1,646 Added 43.2%
5,456 $385,000
Q3 2020

Jun 26, 2023
SELL
$27.04 - $62.21 $170,000 - $391,114
-6,287 Reduced 62.27%
3,810 $146,000
Q2 2020

May 24, 2024
SELL
$20.08 - $40.39 $187,406 - $376,959
-9,333 Reduced 71.01%
3,810 $143 Million
Q2 2020

Jun 26, 2023
SELL
$20.08 - $40.39 $126,242 - $253,931
-6,287 Reduced 62.27%
3,810 $142,000
Q2 2020

Mar 22, 2023
SELL
$20.08 - $40.39 $126,242 - $253,931
-6,287 Reduced 62.27%
3,810 $142,000
Q2 2020

Aug 14, 2020
BUY
$20.08 - $40.39 $76,504 - $153,885
3,810 New
3,810 $143,000

Others Institutions Holding KROS

# of Institutions
174
Shares Held
30.3M
Call Options Held
76.8K
Put Options Held
9K
View Full List

About Keros Therapeutics, Inc.

KROS Quotes by TradingView
  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.46B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email